Immunotherapy drug shows promise for tough skin cancer in early trial

NCT ID NCT06981325

Recruiting now Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jan 12, 2026 · Last updated Apr 30, 2026 · Updated 15 times

Summary

This study tests the drug cemiplimab as a first treatment for people with advanced basal cell carcinoma who have not received prior therapy. About 34 participants will receive the drug to see if it shrinks tumors and how safe it is. The goal is to find a new option for this type of skin cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA (BCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Helios Klinikum Erfurt
RECRUITING

Erfurt, Germany
Helios Klinikum Oberhausen
RECRUITING

Oberhausen, Germany
Johannes Wesling Klinikum
RECRUITING

Minden, Germany
Nationales Centrum für Tumorerkrankungen (NCT)
RECRUITING

Heidelberg, Germany
Universitätsklinikum Erlangen
RECRUITING

Erlangen, Germany
Universitätsklinikum Leipzig
RECRUITING

Leipzig, Germany
Universitätsklinikum Tübingen
RECRUITING

Tübingen, Germany

Conditions

Explore the condition pages connected to this study.

BASAL CELL CARCINOMA (BCC) FIRST LINE TREATMENT